AETHLON MEDICAL INC — Form S-1/A
Filed July 1, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 72/100
What the filing says
Aethlon Medical, Inc. (NASDAQ: AEMD), a $5.7M market cap medical device company, filed Amendment No. 1 to its Form S-1 registration statement on July 1, 2026, for a best-efforts offering of up to 4.7M shares of common stock at $0.85/share plus accompanying common warrants (exercisable at $0.85/share for 5 years post-stockholder approval), plus pre-funded warrants at $0.849 each, targeting $4M gross proceeds. Maxim Group LLC is the exclusive placement agent receiving 6.5% cash fee ($260K) plus warrants to purchase 188,235 shares (4% of issued shares). No minimum closing condition; offering terminates within one year. Company must hold stockholder meeting by October 1, 2026 to approve warrant exercises.
Why this rating
Capital raise of $4M (~70% of market cap) is material and dilutive; warrant overhang creates future dilution risk, but best-efforts structure and no minimum threshold limit upside. Standard biotech financing with moderate execution risk.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.